Impact of Semaglutide on CD34+ EPC and Fat Derived MSC

NCT04126603 on ClinicalTrials.gov · last registry update 2025-09-09

A small phase 4 — 10 participants, against a typical 75. The sponsor logged completion for 25 October 2023. Primary outcome, as filed: CD34+ Endothelial Progenitor Cell Number (EPC) Per Mononuclear Cells (MNC) Ratio. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Sabyasachi Sen
Sponsor type: Other
Enrollment: 10
Started: 2019-08-01
Primary completion: 2023-10-25 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

CD34+ Endothelial Progenitor Cell Number (EPC) Per Mononuclear Cells (MNC) Ratio

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.